New York, Feb 4, 2026, 14:48 EST — Regular session.
AbbVie Inc shares fell 2.5% to $219.98 in afternoon trading Wednesday, hitting a low of $204.98 earlier in the session.
Investors zeroed in on a weaker-than-expected quarter for Rinvoq, one of AbbVie’s top two growth drivers. Still, the company raised its 2026 adjusted profit outlook above Wall Street’s estimates. William Blair’s Matt Phipps flagged “growing competition for the company’s immunology and inflammation franchises,” singling out Johnson & Johnson’s Tremfya. AbbVie CFO Scott Reents also cautioned about “low-single-digit pricing headwinds” as the firm reaffirmed its $31.6 billion 2026 sales target for Rinvoq and Skyrizi. 1
AbbVie’s emphasis is sharpening as the company faces pressure to compensate for Humira, its former blockbuster now challenged by biosimilars—close replicas of the original biologic. CEO Robert A. Michael projected “another year of robust growth in 2026.” 2
AbbVie posted adjusted Q4 earnings of $2.71 per share, with revenue hitting $16.618 billion. Sales of Skyrizi jumped 32.5% to $5.006 billion, and Rinvoq revenue climbed 29.5% to $2.374 billion. Humira, however, saw a 25.9% drop, bringing in $1.246 billion. 3
A regulatory filing revealed the company submitted its earnings release via a Form 8-K on Wednesday. 4
Along with its results, AbbVie announced a three-year pact with the Trump administration aimed at expanding Medicaid discounts and direct-to-patient programs. The company also pledged $100 billion in U.S. R&D and capital investments over the next decade. AbbVie highlighted new Rinvoq filings for non-segmental vitiligo and a wider European submission for migraine drug Aquipta. It secured FDA approval for Epkinly in follicular lymphoma, alongside several oncology and manufacturing deals. 5
AbbVie slipped even as the broader health sector gained ground: the Health Care Select Sector SPDR Fund climbed roughly 1.5%, while the SPY ETF, which tracks the S&P 500, dipped about 0.5%. Johnson & Johnson shares rose nearly 1%.
Wednesday’s wild swings highlighted just how tight the margin for error is in AbbVie’s newer immunology business. Any slowdown in Rinvoq’s growth, tougher pricing pressures, or a steeper-than-anticipated drop in Humira sales could reignite questions about the staying power of AbbVie’s earnings once Humira fades.
Investors are now turning their attention to whether Rinvoq and Skyrizi can maintain strong demand amid rising competition. They’ll also be eyeing the rescheduled U.S. January employment report, set for release Feb. 11 at 8:30 a.m. ET. 6
